Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on September 11, 2018, to report the entry into a material definitive agreement regarding a public offering of common stock. The offering closed on September 14, 2018.
Key Financial Metrics
- Shares Offered: 14,117,647 shares of common stock.
- Offering Price: $4.25 per share.
- Underwriters' Option: A 30-day option to purchase up to 2,117,647 additional shares was granted and exercised in full on September 12, 2018.
- Net Proceeds: Approximately $64.5 million after deducting underwriting discounts and estimated offering expenses.
- Underwriters: Cowen and Company, LLC and Cantor Fitzgerald & Co.
Material Changes
This filing represents a significant capital raise event rather than a change in operating performance. The company increased its equity capital by issuing approximately 16.2 million shares in total (including the option exercise). The filing does not provide comparative financial data for revenue, profit, or cash flow changes versus prior periods.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or specific risk factors beyond standard underwriting indemnification clauses. The proceeds are intended to be used for general corporate purposes, though specific allocation details are not provided in this text. The Underwriting Agreement includes customary representations and warranties, and the Company agreed to indemnify the Underwriters against certain liabilities.
Investor Verification Checklist
- Verify the final closing date and total share count including the exercised option (September 14, 2018).
- Confirm the exact net proceeds received after all transaction costs are finalized.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods or restrictive covenants.
- Check subsequent filings for the stated use of the $64.5 million in proceeds.